Vaccines Press Releases

03.08.2021

Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate

02.26.2021

European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older

02.25.2021

Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants

02.23.2021

U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine)

02.19.2021

Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA

02.18.2021

Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women

02.17.2021

Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®

02.12.2021

U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

02.12.2021

Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine

01.22.2021

Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19

12.29.2020

Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®

12.23.2020

Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine